{"success":true,"data":{"pressRelease":{"id":"157307","rtpr_id":"nBw9Dtgy7a-20260930","ticker":"SRPT","exchange":"NASDAQ","all_tickers":["SRPT"],"title":"Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","author":"Business Wire","published_at":"2026-09-30T20:30:00.273Z","article_body":"Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule\n5635(c)(4)\n\nSarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic\nmedicine for rare diseases, granted equity awards on Sept. 30, 2026 that were\npreviously approved by the Compensation Committee of its Board of Directors\nunder Sarepta’s 2024 Employment Commencement Incentive Plan, as a material\ninducement to employment to 37 individuals hired by Sarepta in the third\nquarter of 2026. The equity awards were approved in accordance with Nasdaq\nListing Rule 5635(c)(4).\n\nThe employees received in the aggregate 211,070 restricted stock units\n(“RSUs”). One-fourth of the RSUs will vest yearly on each anniversary of\nthe Grant Date, such that the RSUs granted to each employee will be fully\nvested on the fourth anniversary of the Grant Date, in each case, subject to\neach such employee’s continued employment with Sarepta on such vesting date.\nEmployees did not receive options to purchase shares of Sarepta’s common\nstock.\n\nAbout Sarepta Therapeutics\n\nSarepta is on an urgent mission: engineer precision genetic medicine for rare\ndiseases that devastate lives and cut futures short. We hold a leadership\nposition in Duchenne muscular dystrophy (Duchenne) and are building a robust\nportfolio of programs across muscle, central nervous system, and cardiac\ndiseases. For more information, please visit www.sarepta.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.sarepta.com&esheet=54613647&newsitemid=20260930166089&lan=en-US&anchor=www.sarepta.com&index=1&md5=8ab9903b44fe2654f4f73df964a0f5d9)\nor follow us on LinkedIn\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fsarepta-therapeutics&esheet=54613647&newsitemid=20260930166089&lan=en-US&anchor=LinkedIn&index=2&md5=d6eeea12e996340ab83e3f47f3bdb84c)\n, X\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Ftwitter.com%2FSarepta&esheet=54613647&newsitemid=20260930166089&lan=en-US&anchor=X&index=3&md5=14036e10c0971d371822478ebf1f1b12)\n, Instagram\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.instagram.com%2Fsareptatherapeutics%2F&esheet=54613647&newsitemid=20260930166089&lan=en-US&anchor=Instagram&index=4&md5=6d601298b170272a93bbd6020d968cb2)\nand Facebook\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.facebook.com%2FSarepta-Therapeutics-208950446535427%2F&esheet=54613647&newsitemid=20260930166089&lan=en-US&anchor=Facebook&index=5&md5=1167e67716d5a004d872aba9d8ccd1f6)\n.\n\nInternet Posting of Information\n\nWe routinely post information that may be important to investors in the 'For\nInvestors' section of our website at www.sarepta.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.sarepta.com%2F&esheet=54613647&newsitemid=20260930166089&lan=en-US&anchor=www.sarepta.com&index=6&md5=56f85d0477b4e0dc2a459eb6b70ea309)\n. We encourage investors and potential investors to consult our website\nregularly for important information about us.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260930166089/en/\n(https://www.businesswire.com/news/home/20260930166089/en/)\n\nInvestors: \n\nIan Estepan, 617-274-4052 iestepan@sarepta.com \n(mailto:iestepan@sarepta.com) \nRyan Wong, 617-800-4112, rwong@sarepta.com \n(mailto:rwong@sarepta.com) \nTam Thornton, 617-803-3825, tthornton@sarepta.com\n(mailto:tthornton@sarepta.com)\n\nMedia: \n\nTracy Sorrentino, 617-301-8566, tsorrentino@sarepta.com\n(mailto:tsorrentino@sarepta.com)\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw9Dtgy7a-20260930","title":"Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","author":"Business Wire","ticker":"SRPT","created":"2026-09-30T20:30:00.273Z","tickers":["SRPT"],"exchange":"NASDAQ","article_body":"Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule\n5635(c)(4)\n\nSarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic\nmedicine for rare diseases, granted equity awards on Sept. 30, 2026 that were\npreviously approved by the Compensation Committee of its Board of Directors\nunder Sarepta’s 2024 Employment Commencement Incentive Plan, as a material\ninducement to employment to 37 individuals hired by Sarepta in the third\nquarter of 2026. The equity awards were approved in accordance with Nasdaq\nListing Rule 5635(c)(4).\n\nThe employees received in the aggregate 211,070 restricted stock units\n(“RSUs”). One-fourth of the RSUs will vest yearly on each anniversary of\nthe Grant Date, such that the RSUs granted to each employee will be fully\nvested on the fourth anniversary of the Grant Date, in each case, subject to\neach such employee’s continued employment with Sarepta on such vesting date.\nEmployees did not receive options to purchase shares of Sarepta’s common\nstock.\n\nAbout Sarepta Therapeutics\n\nSarepta is on an urgent mission: engineer precision genetic medicine for rare\ndiseases that devastate lives and cut futures short. We hold a leadership\nposition in Duchenne muscular dystrophy (Duchenne) and are building a robust\nportfolio of programs across muscle, central nervous system, and cardiac\ndiseases. For more information, please visit www.sarepta.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.sarepta.com&esheet=54613647&newsitemid=20260930166089&lan=en-US&anchor=www.sarepta.com&index=1&md5=8ab9903b44fe2654f4f73df964a0f5d9)\nor follow us on LinkedIn\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fsarepta-therapeutics&esheet=54613647&newsitemid=20260930166089&lan=en-US&anchor=LinkedIn&index=2&md5=d6eeea12e996340ab83e3f47f3bdb84c)\n, X\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Ftwitter.com%2FSarepta&esheet=54613647&newsitemid=20260930166089&lan=en-US&anchor=X&index=3&md5=14036e10c0971d371822478ebf1f1b12)\n, Instagram\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.instagram.com%2Fsareptatherapeutics%2F&esheet=54613647&newsitemid=20260930166089&lan=en-US&anchor=Instagram&index=4&md5=6d601298b170272a93bbd6020d968cb2)\nand Facebook\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.facebook.com%2FSarepta-Therapeutics-208950446535427%2F&esheet=54613647&newsitemid=20260930166089&lan=en-US&anchor=Facebook&index=5&md5=1167e67716d5a004d872aba9d8ccd1f6)\n.\n\nInternet Posting of Information\n\nWe routinely post information that may be important to investors in the 'For\nInvestors' section of our website at www.sarepta.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.sarepta.com%2F&esheet=54613647&newsitemid=20260930166089&lan=en-US&anchor=www.sarepta.com&index=6&md5=56f85d0477b4e0dc2a459eb6b70ea309)\n. We encourage investors and potential investors to consult our website\nregularly for important information about us.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260930166089/en/\n(https://www.businesswire.com/news/home/20260930166089/en/)\n\nInvestors: \n\nIan Estepan, 617-274-4052 iestepan@sarepta.com \n(mailto:iestepan@sarepta.com) \nRyan Wong, 617-800-4112, rwong@sarepta.com \n(mailto:rwong@sarepta.com) \nTam Thornton, 617-803-3825, tthornton@sarepta.com\n(mailto:tthornton@sarepta.com)\n\nMedia: \n\nTracy Sorrentino, 617-301-8566, tsorrentino@sarepta.com\n(mailto:tsorrentino@sarepta.com)\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-09-30T20:30:00.386894154Z","server_sent_at_ms":1790800200386},"received_at":"2026-09-30T20:30:00.438Z","source_url":"https://www.businesswire.com/news/home/20260930166089/en/"},"analysis":{"id":"145974","press_release_id":"157307","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Sarepta Therapeutics granted 211,070 restricted stock units as inducement awards to 37 employees hired in the third quarter of 2026.\n\nThe awards were made under the company's 2024 Employment Commencement Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4), with annual vesting over four years.\n\nThis is routine compensation housekeeping with no material financial or pipeline impact.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine inducement grant disclosure -- no actionable content; suppress."},"keyFigures":{"customDimensions":{"vesting":"25% annually, fully vested on fourth anniversary of grant date","rsus_granted":211070,"employees_affected":37}},"namedEntities":{"people":[],"products":[],"companies":[{"name":"Sarepta Therapeutics, Inc.","ticker":"SRPT","relationship":"filer/issuer"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Boilerplate Nasdaq Rule 5635(c)(4) inducement grant disclosure for 37 new hires totaling 211,070 RSUs. Routine equity compensation housekeeping with no earnings, pipeline, or capital-structure implications."},"tickerRelevance":{"others":[],"primary":"SRPT"},"globalImportance":5,"audienceRelevance":5,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid-cap-biotech","boilerplate":true,"eventGravity":"routine-equity-grants","issuerAuthored":true}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Sarepta Therapeutics granted 211,070 restricted stock units as inducement awards to 37 employees hired in the third quarter of 2026.\n\nThe awards were made under the company's 2024 Employment Commencement Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4), with annual vesting over four years.\n\nThis is routine compensation housekeeping with no material financial or pipeline impact.","key_figures":{"customDimensions":{"vesting":"25% annually, fully vested on fourth anniversary of grant date","rsus_granted":211070,"employees_affected":37}},"named_entities":{"people":[],"products":[],"companies":[{"name":"Sarepta Therapeutics, Inc.","ticker":"SRPT","relationship":"filer/issuer"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-30T20:30:05.177Z","global_importance":5,"audience_relevance":5,"importance_components":{"tickerTier":"mid-cap-biotech","boilerplate":true,"eventGravity":"routine-equity-grants","issuerAuthored":true}},"durationMs":4702,"modelName":"glm-5.3-flashx"}}